



# **From dysgammaglobulinemia to autosomal dominant activation-induced cytidine deaminase deficiency: unraveling the mystery behind an inherited immunodeficiency first described 56 years ago**

Jehane Fadlallah, Loic Chentout, Bertrand Boisson, Aurore Pouliet, Cecile Masson, Florence Morin, Anne Durandy, Jean-Laurent Casanova, Eric Oksenhendler, Sven Kracker

## **► To cite this version:**

Jehane Fadlallah, Loic Chentout, Bertrand Boisson, Aurore Pouliet, Cecile Masson, et al.. From dysgammaglobulinemia to autosomal dominant activation-induced cytidine deaminase deficiency: unraveling the mystery behind an inherited immunodeficiency first described 56 years ago. The Journal of Pediatrics, 2020, 223, 10.1016/j.jpeds.2020.03.024 . hal-03009448

**HAL Id: hal-03009448**

**<https://hal.science/hal-03009448>**

Submitted on 17 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**From dysgammaglobulinemia to autosomal dominant activation-induced cytidine deaminase deficiency: unraveling the mystery behind an inherited immunodeficiency first described 56 years ago**

Jehane Fadlallah, M.D., Ph.D.<sup>1</sup>, Loic Chentout M.S.<sup>2</sup>, Bertrand Boisson Ph.D.<sup>3</sup>, Aurore Pouliet B.S.<sup>4</sup>, Cecile Masson M.S.<sup>5</sup>, Florence Morin PharmD.<sup>6</sup>, Anne Durandy M.D.<sup>2</sup>, Jean-Laurent Casanova M.D.,Ph.D.<sup>3,7,8,9</sup>, Eric Oksenhendler M.D.<sup>1\*</sup>, Sven Kracker Ph.D.<sup>2\*</sup>

\* E. Oksenhendler and S. Kracker contributed equally to this article.

<sup>1</sup> Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, and Paris Diderot University, France,

<sup>2</sup> Human Lymphohematopoiesis Laboratory, Institut Imagine, INSERM U1163, Paris Descartes Sorbonne, Paris Cite University, France

<sup>3</sup> Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR1163, Paris, France and the St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University, New York, USA.

<sup>4</sup> Genomics Core Facility, Institut Imagine, INSERM U1163, Paris Descartes Sorbonne, Paris Cite University, France

<sup>5</sup> Bioinformatics Facility, Institut Imagine, INSERM U1163, Paris Descartes Sorbonne, Paris Cite University, France

<sup>6</sup> Immunology and Histocompatibility Laboratory, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Paris, France

<sup>7</sup> Howard Hughes Medical Institute, New York, USA

<sup>8</sup> Rockefeller University and Rockefeller University Hospital

<sup>9</sup> Pediatric Immunology and Hematology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris, France

***In memoriam: Fred Rosen***

Corresponding authors: Eric Oksenhendler

Département d'Immunologie Clinique

Hôpital Saint-Louis

1 avenue Claude Vellefaux, 75010, Paris, France

Tel: +33 142499690

Fax: +33 142499472

Mail: [eric.oksenhendler@aphp.fr](mailto:eric.oksenhendler@aphp.fr)

Jehane Fadlallah

Département d'Immunologie Clinique

Hôpital Saint-Louis

1 avenue Claude Vellefaux, 75010, Paris, France

Mail : [jehane.fadlallah@aphp.fr](mailto:jehane.fadlallah@aphp.fr)

The study was funded by INSERM, the Agence National de la Recherche, as part of the Investment for the Future Program (ANR-10-IAHU-01) and by ANR-19-CE17-0012-01 (ANR-AID), ANR-14-CE15-0009, the Ligue Contre le Cancer–Comité de Paris, the Fondation

ARC Pour la Recherche sur le Cancer, and the Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), the Rockefeller University, Paris Descartes University, and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (P01AI061093).

## **Summary**

The genetic investigation of a family presenting with a dominant form of hyper-IgM syndrome published in 1963 and 1975, revealed a R190X nonsense mutation in activation-induced cytidine deaminase. This report illustrates over six decades how progress has been made in the characterization of primary immunodeficiencies, from immunochemistry to whole-exome sequencing.

In 1963, Fred Rosen and James Bougas reported on a 37-year-old woman (proband II-12) having suffered from recurrent infections and severe bronchiectasis over the previous ten years(1). Immuno-electrophoresis of the patient's serum highlighted elevation of the 19S- $\gamma$ 1 globulin fraction and a profoundly low 7S- $\gamma$  globulin fraction. The features of the 1963 case were reminiscent of Dr. Rosen's description of two boys in 1961(2).

In 1975, Feldman *et al.* studied one of the proband II-12's nephews (III-2) and then described in the *Journal of Pediatrics*, the clinical and biological features of 37 family members over three generations (3). The researchers identified immunological abnormalities in 12 relatives, although only three of these presented with recurrent infections. Ten family members had elevated serum immunoglobulin (Ig) M levels, and seven had low serum levels of IgG, IgA, or both. In most family members, the lymphocyte count (assessed by the percentage of E-rosette-forming lymphocytes and the percentage of immunoglobulin-bearing cells) was within the normal range. Analysis of the family's pedigree over three generations suggested that the antibody deficiency had an autosomal dominant (AD) mode of inheritance. This kindred was the first to be diagnosed with an AD form of an immunological and clinical condition that was designated "hyper IgM syndrome" (HIGM) in 1979(4).

Hyper-IgM syndrome encompasses a number of genetic defects that impair class switch recombination (CSR) and somatic hypermutation (SHM) and result in normal or elevated serum IgM levels and abnormally low serum levels of other Igs. The first kindreds with X-linked recessive (XR) and autosomal recessive (AR) forms of HIGM had been reported in 1961(5) and 1994(6, 7), respectively. In 1993, the first HIGM-causing genetic defect was identified; an X-linked CD40 ligand deficiency was found to cause the most common XR form of this syndrome (8-10),(11). Mutations in the *AICDA* gene (encoding activation-induced cytidine deaminase (AID)) responsible for the most frequent AR form of HIGM were described in 2000(12).

Activation-induced cytidine deaminase initiates the B-cell specific CSR and SHM processes(13). It is now known that a range of biallelic mutations, premature stop codons and deletions in *AICDA* affect both CSR and SHM (12, 14). Along with the AR form of HIGM, *AICDA* is also involved in a rare AD form of HIGM that was genetically characterized for the first time in 2003 in a Japanese woman with a mild clinical phenotype(15). The causative heterozygous R190X mutation in *AICDA* generates a premature stop codon in exon 5 and results in the loss of the last nine C-terminal amino acids in the AID protein (part of the nuclear export signal domain). In 2005, Imai *et al.* demonstrated that the R190X mutation was associated with an impairment in CSR but – in contrast to AR HIGM – not in SHM(16).

In 2018, one of the initial patient's nieces (III-8) underwent genetic testing in our center. Here, we report on how the cause of a rare AD primary immunodeficiency (PID) first described in 1963 was determined<sup>1</sup>. This investigation of an AD inherited HIGM neatly illustrates the remarkable progress made in the exploration of PIDs over the last 6 decades.

## **Methods**

### **PATIENTS**

Proband III-8 and her three children underwent a physical examination. New or updated clinical information was obtained for all family members. A blood sample was obtained from proband III-8 and 10 of her relatives. All assessed family members had given their written, informed consent to participation in genetic testing.

### **SERUM IMMUNOGLOBULIN ASSAY**

Serum IgG, IgA and IgM levels were measured in a nephelometric assay.

### **LYMPHOCYTE SUBSET PHENOTYPING**

B, T and NK cell subsets were measured using flow cytometry (FACS CANTO II, Becton Dickinson, Franklin Lakes, NJ, USA). Naive and memory T-cell subsets and naive, transitional, marginal zone and memory B-cell subsets were determined in proband III-8.

#### **WHOLE-EXOME SEQUENCING AND SANGER SEQUENCING**

Genomic DNA was extracted from leukocytes provided by 11 family members. For proband III-8, barcoded exome libraries were prepared and sequenced with the NovaSeq6000 system (Illumina). Sequences were then mapped on the human reference genome (NCBI build 37, hg19 version). Variants were called with the Genome Analysis Toolkit (GATK), SAMtools, and Picard tools. All the variants were annotated and filtered with PolyWeb (our in-house annotation software; see the Supplementary Appendix). Sanger sequencing was used to detect the R190X mutation in all tested relatives.

### **Results**

Proband III-8 (a 60-year-old woman) had suffered from recurrent bronchitis since childhood. There was no evidence of an auto-immune or lymphoproliferative disorder. The proband had never received IgG replacement therapy. Blood tests confirmed the diagnosis of HIGM, with an elevated level of IgM and normal levels of IgG and IgA (Table 1), and lymphocyte immunophenotyping show that neither the switched memory B-cell (CD19<sup>+</sup>CD27<sup>+</sup>IgD<sup>-</sup>) population nor the T-cell compartment was defective (data not shown). The proband exhibited normal IgG titers against tetanus toxin and protective titers against 6 out of 7 *Streptococcus pneumoniae* serotypes (post pneumococcal polysaccharide vaccine).

By combining the family's data from the 1975 study(3) with the recently updated information, we determined that 15 members had presented with recurrent respiratory infections – typically



from late childhood/early adulthood. Nevertheless, only 6 out of the 15 members had received IgG replacement therapy (Figure 1). We had the opportunity to compare serum immunoglobulin levels in four patients, 44 years apart (1975 and 2019). Three patients exhibited persistent high IgM levels while the fourth patient kept with normal IgM levels. All four patients had persistent low IgA levels. Hence, the serum Ig defects varied from one individual to another but were stable over time (Table 1).

To identify the genetic cause of the disease, genomic DNA from proband III-8 was whole-exome sequenced. In view of the mode of inheritance, an AD genetic model was used to filter the identified genetic variants (Supplementary Figure). A heterozygous C-to-T nonsense mutation at position g.8756909 (GRCH37; NM\_020661.2) on chromosome 12 (c.568 C>T in exon 5 of the AICDA gene) was detected. This variant was absent from the gnomAD database (<https://gnomad.broadinstitute.org>) and in Polyweb, an in-house database containing 16060 WES and 744 WGS. The R190X heterozygous nonsense mutation in AID has been linked to an AD HIGM syndrome with a mild clinical phenotype, hypogammaglobulinemia of variable intensity, conserved SHM, and a variable disruption of CSR(15, 16)(17).

Sanger sequencing confirmed the presence of a heterozygous R190X mutation in proband III-8 and in six symptomatic family members (Figure 1), all of whom suffered from recurrent infections. Five of the seven individuals had HIGM syndrome with various IgG and/or IgA defects, and three were receiving IgG replacement therapy (Table 1). We also genotyped four asymptomatic relatives born to carriers: neither proband III-16 nor the three asymptomatic children of proband III-8 carried the R190X mutation. It is noteworthy that proband III-16 had been considered to be asymptomatic in 1975 but had since developed non-Hodgkin lymphoma and secondary immunodeficiency requiring IgG replacement therapy.

An analysis of the family's pedigree highlighted the presence of the heterozygous R190X mutation with Mendelian segregation and variable phenotypic expression and in males and females over three generations(3) (Figure 1).

## **Discussion**

Here, we described the largest yet kindred with AD HIGM caused by AID R190X mutation. As in the few previously reported families, the clinical and biological phenotype was variable yet mild in most investigated patients. This rare PID has only been included in the latest International Classification of Human Inborn Errors of Immunity (18).

The underlying molecular pathophysiological mechanism involving disruption of Ig CSR and maintenance of SHM remain elusive. AID haploinsufficiency is unlikely since entire deletion of one *AICDA* allele does not impact B-cell function. A dominant negative effect seem rather plausible either by modifying the C-terminal anchor needed for the binding of the CSR co-factors, or either by the nuclear accumulation of the mutated protein, altering the native protein function(16, 17). Functional investigation provided evidence that the domain encoded by exon 5 of the *AICDA* gene provides a link between DNA damage and repair during CSR(19, 20).

In four tested patients, a pair of serum Ig measurements 44 years apart revealed the persistence of abnormal Ig levels. The kindred's medical history nicely illustrates the technical progress achieved over the last six decades in the investigation of PIDs. In 1963, Rosen and Bougas (1) first investigated proband II-12 for recurrent infections and bronchiectasis; the researchers used the available immunochemical methods to characterize what was referred to as "dysgammaglobulinemia". At that time, serum immunoglobulins were classified in three distinct fractions (7S- $\gamma$ 2, 7S- $\gamma$ 1 and 19S- $\gamma$ 1, where S was the sedimentation constant) on the basis of their electrophoretic and ultracentrifugation properties. In 1964 (i.e. one year after Rosen et al.'s report), the World Health Organization designated the 19S  $\gamma$ -globulin as "IgM"(21). Immunoelectrophoresis (based on goat anti-19S gammaglobulin, horse anti-

gammaglobulin and horse anti-human serum) was used to distinguish more precisely between the different immunoglobulins (22). Thus, proband II-12 was found to have an elevated 19S- $\gamma$ 1 fraction and no 7S- $\gamma$ 1 and  $\gamma$ 2 fractions. Furthermore, vaccine responses and isohemagglutination tests for Gram-negative bacteria bearing O and H antigens were used as functional assays. No anti-H antibodies were found, since they are present in the 7S- $\gamma$ 2 fraction only. In contrast, anti-O antibodies (present in the 19S- $\gamma$ 1 fraction) were conserved in proband II-12. Twelve years later (i.e. in 1975), progress in immunologic techniques had enabled scientists to distinguish between T and B lymphocytes. T-cell counts were assessed by determining the percentage of lymphocytes that formed rosettes with sheep red blood cells. B-cell counts were evaluated in an immunofluorescence assay after the lymphocytes had been staining with a fluorescein-conjugated specific goat anti-human heavy chain antibody. Immunoglobulin-bearing cells (defined by the presence of a uniform rim or patchy surface fluorescence) were considered to be B-cells. In proband II-12, E-rosette forming lymphocytes fell within normal range (79% for a normal range of 52-86%) whereas "Immunoglobulins bearing cells" were decreased for IgG and IgA (1% and 2% respectively)(3). In the following years, the advent of fluorescence-activated cell sorting considerably improved the process of lymphocyte phenotyping. In the last decade, the investigation of PIDs has been dominated by genetics. Although Sanger sequencing of candidate genes involved in the immune system has been used since 1980, whole-exome sequencing is now the reference technique for uncovering the involvement of novel genes and revealing new modes of transmission. To date, more than 400 genes have been causally implicated in PIDs, and the number is increasing exponentially year after year(23). Nevertheless, pathophysiological investigation is complicated when several different types of mutation (e.g. gain- of-function and loss-of-function mutations) in a single gene are involved or (as in the present case) when the PID features differ in the mode of inheritance (either recessive or dominant).



### **Author Affiliations**

From the Department of Clinical Immunology (J.F., E.O.), the Immunology and Histocompatibility Laboratory (F.M.), Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris; the Paris-Diderot, Paris Cite University (J.F., E.O.); the Human Lymphohematopoiesis Laboratory (L.C., A.D., S.K.), the Genomics Core Facility (A.P.), the Bioinformatics Facility (C.M.), Institut Imagine, INSERM U1163, Paris Descartes Sorbonne, Paris Cite University, - all in Paris ; the Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR1163, 75015 Paris, France and the St. Giles Laboratory of Human Genetics of Infectious Diseases, New York, (B.B., J-L.C.); the Howard Hughes Medical Institute, the Rockefeller University, the Rockefeller University Hospital, New York and the Necker Hospital and School of Medicine, Paris Descartes University (J-L.C.)

### **Acknowledgments**

We thank the participating family for their cooperation. SK is a Centre National de la Recherche Scientifique staff researcher.


**Table 1:** Clinical and immunologic characteristics of the 11 family members having undergone genetic testing.

Family member	Sex	Age (years)	AID	Clinical phenotype	Serum immunoglobulins		
					IgG (mg/dL)	IgA (mg/dL)	IgM (mg/dL)
II-2	F	38	R190X/WT	Recurrent infections Mouth ulcers	<i><b>140</b></i>	<i><b>12</b></i>	<i><b>420</b></i>
III-2	M	83	R190X/WT	Recurrent infections Erythema nodosa	1064*	< <b>5</b>	<b>554</b>
		9			<i><b>300</b></i>	< <b>5</b>	<i>125</i>
III-7	M	54	R190X/WT	Recurrent infections	2027*	< <b>5</b>	135
		19			<i>740</i>	<b>63</b>	<i><b>260</b></i>
III-8	F	64	R190X/WT	Recurrent infections	1241	<b>47</b>	<b>306</b>
		15			<i>740</i>	<b>70</b>	<i><b>438</b></i>
III-15	M	60	R190X/WT	Recurrent infections	710	<b>103</b>	<b>587</b>
		65			1047 *	< <b>5</b>	<b>466</b>
III-16	M	63	WT/WT	Non-Hodgkin lymphoma	1300 *	304	73
IV-1	F	22	WT/WT	Asymptomatic	1075	225	113
IV-2	F	19	WT/WT	Asymptomatic	1318	137	<b>221</b>
IV-3	M	18	WT/WT	Asymptomatic	978	122	97
IV-4	F	34	R190X/WT	Recurrent infections	792	<b>58</b>	<b>224</b>
IV-5	M	28	R190X/WT	Recurrent infections	<b>68</b>	< <b>5</b>	145

AID: activation-induced cytidine deaminase; WT: wild type. Age and serum immunoglobulin values in italics are taken from Feldman et al.'s 1975 study (ref 3); \* receiving immunoglobulin replacement therapy; values in bold: outside the normal range. Normal ranges were defined as follows: IgG: 675–1253 mg/dL; IgA: 104–337 mg/dL; IgM: 52–146 mg/dL.

## Figure legends

**Figure 1:** (A) The pedigree of the family displaying an autosomal dominant inherited trait. Members having undergone genetic testing are either C/C (wild type) or C/T (carriers of the R190X mutation). Black filled symbols represent affected members with recurrent infections and abnormal serum Ig levels; \* denotes Ig replacement therapy; the arrow denotes the proband in the present study. (B) Electropherogram showing the c.568 C>T mutation (generating a STOP codon) in proband III-8, compared with proband III-16. (C) Graphical representation of the AID protein, showing the R190X mutation in the C-terminal domain.



## References

1. Rosen FS, Bougas JA. Acquired Dysgammaglobulinemia: Elevation of the 19s Gamma Globulin and Deficiency of the 7s Gamma Globulin in a Woman with Chronic Progressive Bronchiectasis. *The New England journal of medicine*. 1963;269:1336-40.
2. Rosen FS, Kevy SV, Merler E, Janeway CA, Gitlin D. Recurrent bacterial infections and dysgamma-globulinemia: deficiency of 7S gamma-globulins in the presence of elevated 19S gamma-globulins. Report of two cases. *Pediatrics*. 1961;28:182-95.
3. Feldman G, Koziner B, Talamo R, Bloch KJ. Familial variable immunodeficiency: autosomal dominant pattern of inheritance with variable expression of the defect(s). *The Journal of pediatrics*. 1975;87(4):534-9.
4. Immunodeficiency. Report of a WHO scientific group. *Clinical immunology and immunopathology*. 1979;13(3):296-359.
5. Jamieson WM, Kerr MR. A family with several cases of hypogammaglobulinaemia. *Archives of disease in childhood*. 1962;37:330-6.
6. Conley ME, Larche M, Bonagura VR, Lawton AR, 3rd, Buckley RH, Fu SM, et al. Hyper IgM syndrome associated with defective CD40-mediated B cell activation. *The Journal of clinical investigation*. 1994;94(4):1404-9.
7. Callard RE, Smith SH, Herbert J, Morgan G, Padayachee M, Lederman S, et al. CD40 ligand (CD40L) expression and B cell function in agammaglobulinemia with normal or elevated levels of IgM (HIM). Comparison of X-linked, autosomal recessive, and non-X-linked forms of the disease, and obligate carriers. *Journal of immunology*. 1994;153(7):3295-306.



8. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. *Nature*. 1993;361(6412):539-41.
9. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. *Nature*. 1993;361(6412):541-3.
10. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. *Cell*. 1993;72(2):291-300.
11. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. *Science*. 1993;259(5097):990-3.
12. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell*. 2000;102(5):565-75.
13. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates *E. coli* suggesting a DNA deamination mechanism for antibody diversification. *Nature*. 2002;418(6893):99-103.
14. Minegishi Y, Lavoie A, Cunningham-Rundles C, Bedard PM, Hebert J, Cote L, et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. *Clinical immunology*. 2000;97(3):203-10.
15. Kasahara Y, Kaneko H, Fukao T, Terada T, Asano T, Kasahara K, et al. Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminase. *The Journal of allergy and clinical immunology*. 2003;112(4):755-60.

16. Imai K, Zhu Y, Revy P, Morio T, Mizutani S, Fischer A, et al. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. *Clinical immunology*. 2005;115(3):277-85.
17. Ta VT, Nagaoka H, Catalan N, Durandy A, Fischer A, Imai K, et al. AID mutant analyses indicate requirement for class-switch-specific cofactors. *Nature immunology*. 2003;4(9):843-8.
18. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. *Journal of clinical immunology*. 2020.
19. Zahn A, Eranki AK, Patenaude AM, Methot SP, Fifield H, Cortizas EM, et al. Activation induced deaminase C-terminal domain links DNA breaks to end protection and repair during class switch recombination. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(11):E988-97.
20. Kracker S, Imai K, Gardes P, Ochs HD, Fischer A, Durandy AH. Impaired induction of DNA lesions during immunoglobulin class-switch recombination in humans influences end-joining repair. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(51):22225-30.
21. Cooper MD, Faulk WP, Fudenberg HH, Good RA, Hitzig W, Kunkel H, et al. Classification of primary immunodeficiencies. *N Engl J Med*. 1973;288(18):966-7.
22. Scheidegger JJ. [A micro-method of immuno-electrophoresis]. *International archives of allergy and applied immunology*. 1955;7(2):103-10.
23. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency

Diseases Committee Report on Inborn Errors of Immunity. Journal of clinical immunology.  
2018;38(1):96-128.

## **Supplementary appendix: methods**

### **WHOLE-EXOME SEQUENCING**

After genomic DNA had been extracted from leukocytes, exome libraries were generated with the Twist Bioscience kit (Human RefSeq Exome Kit, 36 Mb, Twist Bioscience). Briefly, genomic DNA (500 ng) was sheared in an ultrasonicator (Covaris). Fifty nanograms of fragmented, purified, double-strand genomic DNA were used to prepare Twist exome libraries according to the manufacturer's instructions (albeit in the absence of initial enzymatic shearing) and with the addition of unique molecular identifiers (barcode adaptors, IDT). Barcoded exome libraries were pooled and sequenced with the NovaSeq6000 system (Illumina), which generated paired-end reads (100 bases + 100 bases). After demultiplexing, sequences were mapped on the human reference genome (NCBI build 37, hg19 version) using BWA, and variants were called with the GATK, SAMtools, and Picard tools. The mean depth of coverage obtained was 100X; 98% of the targeted exonic bases were covered by at least by 15 independent reads, and 97.6% were covered by at least 30 independent reads. Single-nucleotide variants were called with GATK Unified Genotyper, whereas indel calls were made with the GATK IndelGenotyper\_v2. All variants with a read coverage  $\leq 2x$  and a Phred-scaled quality of  $\leq 20$  were filtered out. All the variants were annotated and filtered with PolyWeb (our in-house annotation software).

### **SANGER SEQUENCING**

PCR-amplified DNA was sequenced using a BigDye Terminator v3.1 Cycle Sequencing Kit and a 3500/3500xL Genetic Analyzer (both from Applied Biosystems), according to the manufacturer's instructions. The forward primer was 5'-CCAACCTCGTTTTGAAGCCA-3' and the reverse primer was 5'-GCCAGACCTGTGTTCTTCT-3'. The forward primer was also used for the sequencing reaction.

**Supplementary Table S1. Filtering of annotated variants after whole-exome sequencing with an autosomal dominant genetic model.**

	Number of annotated variants
	Patient III-8
Total	141,554
Non-synonymous, essential splicing, frameshift and stop-gained variants, and indels	15,975
MAF* < .01 (1%)	1,534
MAF* < .001 (0.1%)	977
MAF* < .0001 (0.01%)	711
Removal of pipeline artefacts (in-house MAF data; in one other project only)	181
Non-synonymous variants	150
Frameshift variants	21
Essential splicing variants	6
Stop-gained variants	4
CADD score $\geq 20$	83
CADD score $\geq 25$	42
HGMD	1

MAF: minor allele frequency. \* in the Exome Aggregation Consortium database; 1000 Genomes Project; National Heart, Lung and Blood Institute Exome Sequencing Project. CADD: Combined Annotation Dependent Depletion. HGMD: Human Gene Mutation Database.